košarica
0.00 €Semaglutide
10 mg8% purityLot #SEMAGL-2026-001
Šifra odabrane dimenzije: PEP-SEMA-10MG
Semaglutide is a synthetic agonist of the GLP-1 (Glucagon-Like Peptide-1) receptor that shares approximately 94% structural similarity with endogenous human GLP-1. Initially designed as a therapeutic option for type 2 diabetes, it has since become one of the most extensively studied compounds in metabolic science. By replicating the activity of the natural incretin hormone GLP-1, Semaglutide activates GLP-1 receptors located throughout the pancreas, central nervous system, and gastrointestinal tract. This receptor stimulation promotes glucose-dependent insulin secretion, reduces glucagon output, slows the rate of gastric emptying, and influences hypothalamic pathways involved in appetite regulation, leading to lower caloric intake. Findings from the STEP (Semaglutide Treatment Effect in People with Obesity) clinical program reported average body weight reductions ranging from 14.9% to 17.4% over a 68-week period. Additional studies published in the New England Journal of Medicine have demonstrated meaningful cardiovascular benefits, including a reduced incidence of major adverse cardiovascular events.
€230.58s PDV-om
✅ na zalihi (40)
Količinski popusti
| Količina | Cijena / kom | Ušteda |
|---|---|---|
| 1 vial | 230.58 € | — |
| 3 vials (−7%) | 214.72 € | −7% |
| 5 vials (−12%) | 202.52 € | −12% |
Ocene in mnenja
Prijavite se in ocenite izdelek po prejetem naročilu. prijava
Certifikat analize
Lab verificirano✓Pogledajte COA prije kupnje — transparentnost zajamčena
Istraživački profil
Semaglutide — znanstveni profil
Sadržaj je namijenjen obrazovnim i istraživačkim svrhama. Research Use Only.
- Semaglutide is a synthetic agonist of the GLP-1 (Glucagon-Like Peptide-1) receptor that shares approximately 94% structural similarity with endogenous human GLP-1. Initially designed as a therapeutic option for type 2 diabetes, it has since become one of the most extensively studied compounds in metabolic science. By replicating the activity of the natural incretin hormone GLP-1, Semaglutide activates GLP-1 receptors located throughout the pancreas, central nervous system, and gastrointestinal tract. This receptor stimulation promotes glucose-dependent insulin secretion, reduces glucagon output, slows the rate of gastric emptying, and influences hypothalamic pathways involved in appetite regulation, leading to lower caloric intake. Findings from the STEP (Semaglutide Treatment Effect in People with Obesity) clinical program reported average body weight reductions ranging from 14.9% to 17.4% over a 68-week period. Additional studies published in the New England Journal of Medicine have demonstrated meaningful cardiovascular benefits, including a reduced incidence of major adverse cardiovascular events.
%22%20stroke-width%3D%223%22%2F%3E%3Ccircle%20cx%3D%2278%22%20cy%3D%2292%22%20r%3D%228%22%20fill%3D%22var(--pep-gray-light)%22%2F%3E%3Cpath%20d%3D%22M55%20125%20L95%2095%20L125%20115%20L145%2090%22%20fill%3D%22none%22%20stroke%3D%22var(--pep-gray-light)%22%20stroke-width%3D%223%22%20stroke-linecap%3D%22round%22%20stroke-linejoin%3D%22round%22%2F%3E%3C%2Fsvg%3E)